PART VI. SUMMARY OF THE RISK MANAGEMENT PLAN Summary of risk management plan for ZINFORO
|
|
- Brittney Chase
- 5 years ago
- Views:
Transcription
1 PART VI. SUMMARY OF THE RISK MANAGEMENT PLAN Summary of risk management plan for ZINFORO This is a summary of the risk management plan (RMP) for ZINFORO. The RMP details important risks of ZINFORO, how these risks can be minimised, and how more information will be obtained about ZINFORO's risks and uncertainties (missing information). ZINFORO's SmPC and its package leaflet give essential information to healthcare professionals and patients on how ZINFORO should be used. This summary of the RMP for ZINFORO should be read in the context of all this information including the assessment report of the evaluation and its plain-language summary, all which is part of the European Public Assessment Report (EPAR). Important new concerns or changes to the current ones will be included in updates of ZINFORO's RMP. I. The Medicine and What It Is Used For ZINFORO's is authorised for complicated skin and soft tissue infections (cssti) and community-acquired pneumonia (CAP). It contains ceftaroline fosamil as the active substance and it is given by infusion. Further information about the evaluation of ZINFORO s benefits can be found in ZINFORO's EPAR, including in its plain-language summary, available on the EMA website, under the medicine s webpage uman_med_ jsp&mid=wc0b01ac058001d124 II. Risks Associated with the Medicine and Activities to Minimise or Further Characterise the Risks Important risks of ZINFORO, together with to minimise such risks and the proposed studies for learning more about ZINFORO's risks, are outlined below. Measures to minimise the risks identified for medicinal products can be: Specific Information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals Important advice on the medicine s packaging; The authorised pack size the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly; The medicine s legal status the way a medicine is supplied to the public (e.g. with or without prescription) can help to minimise its risks.
2 Together, these constitute routine risk minimisation. In addition to these, information about adverse events is collected continuously and regularly analysed, including PSUR assessment, so that immediate action can be taken as necessary. These constitute routine pharmacovigilance activities. If important information that may affect the safe use of ZINFORO is not yet available, it is listed under missing information below. II.A. List of Important Risks and Missing Information Important risks of ZINFORO are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of ZINFORO. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (eg, on the long-term use of the medicine). The MAH proposes to reclassify Hypersensitivity/anaphylaxis and CDAD, from important identified risks to risks not important, and therefore to remove them from the list of safety concerns. Table 1. Important identified risks Important potential risks Missing information List of Important Risks and Missing Information CDAD Hypersensitivity/anaphylaxis None Bacterial resistance development Convulsions/seizures Drug induced liver injury Haemolytic anaemia Renal impairment (including potential drug interactions with nephrotoxic agents) Potential for off-label use Immunocompromised population Lactation Paediatric population exposure Pre-existing seizure disorder Pre-existing significant hepatic disease Pregnancy exposure Efficacy in MRSA CAP CAP = Community-acquired pneumonia; CDAD = Clostridium difficile associated diarrhoea; DILI = Drug-induced liver injury; MRSA = Methicillin-resistant Staphylococcus aureus. Strikethrough text: important identified risks reclassified as not important, and therefore removed from the list of safety concerns. II.B. Summary of Important Risks The following 2 safety concerns, previously considered important identified risks, are proposed to be reclassified as not important (strikethrough text in tables below):
3 Clostridium difficile associated diarrhoea (Table 2) Hypersensitivity/anaphylaxis (Table 3) Table 2. Important Identified Risk - Clostridium difficile associated diarrhoea The MAH considers that CDAD can be re-categorised not important, being an adverse reaction with clinical consequences, even serious, but occurring with a low frequency and considered to be acceptable in relation to the severity of the indication treated; in addition, CDAD is a known risk that does not impact on the benefit-risk balance of the product. Chief risk factors include: prior antibiotic exposure, hospitalisation; and age >65 years. Outpatient populations should also be recognised as being at potential risk. Cephalosporins (especially second and third-generation) are among the most common antibiotics implicated in CDAD. RMMs: the risk is communicated through the label in SmPC Section 4.4 (Special warnings and precautions for use) and Section 4.8 (Undesirable effects) CDAD = Clostridium difficile associated diarrhoea; MAH = Marketing authorisation holder; RMM = Risk minimisation measure; SmPC = Summary of product characteristics. Table 3. Important Identified Risk - Hypersensitivity/Anaphylaxis The MAH believes that Hypersensitivity/anaphylaxis can be reclassified as not important because it is an adverse reaction already well-known to health professionals, that does not require additional pharmacovigilance activities or additional risk minimisation, and it has no impact on public health. The most important risk factor for allergy to cephalosporins is a history of hypersensitivity to penicillins or cephalosporins. Atopic individuals, especially those with asthma, may be predisposed to more severe and even fatal reactions in the event of anaphylaxis; however, a history of atopy (allergic rhinitis, asthma, or atopic dermatitis) by itself does not seem to be an independent risk factor for the development of an allergy to β-lactam antibiotics. 1 Routine RMMs: the risk is communicated through the label in SmPC Section 4.3 (Contraindications), Section 4.4 (Special warnings and precautions for use), and Section 4.8 (Undesirable effects). MAH = Marketing authorisation holder; RMM = measure; SmPC = Summary of product characteristics. Table 4. Important Potential Risk Bacterial Resistance Development Bacterial resistance development has been observed in nonclinical studies, and reports indicative of bacterial resistance development have been received in the post-marketing setting.
4 Table 4. Important Potential Risk Bacterial Resistance Development Additional pharmacovigilance activities Factors that may contribute to the development of resistance include inadequate infection control, high antibiotic use in a specific geographic area per unit time, increased use for prophylaxis, increased use for empiric polymicrobial therapy, greater severity of illness of hospitalised patients, more severely immunocompromised patients, devices and procedures, agricultural use of antimicrobials, social factors, international travel, and evolution of pathogens. Evidence suggests that a causal relationship exists between antimicrobial usage and antimicrobial resistance (e.g., hospitals with high antibiotic use have high rates of resistance; changes in antimicrobial usage in such settings are often accompanied by changes in resistance patterns and an increased duration of antimicrobial exposure is accompanied by an increased risk of colonisation with resistant organisms). 2 Routine RMMs: the risk is communicated through the label in SmPC Section (4.1 Therapeutic indications) and Section 5.1 (Pharmacodynamic properties) Additional pharmacovigilance activities: Resistance surveillance programme. See section II.C of this summary for an overview of the post-authorisation development plan. RMM = measure; SmPC = Summary of product characteristics. Table 5. Important Potential Risk Convulsions/Seizures Convulsions/seizures is a recognised class effect and it has been observed in nonclinical studies; reports indicative of convulsions/seizures have been received in clinical trials and in the post-marketing setting. Risk factors include advanced age, history of head trauma or neurologic disease, stroke, brain tumours, renal failure or genetic predisposition. Abnormal neurological status, defined as abnormal neurological examination, abnormal CT brain scan, remote symptomatic aetiology or neurological deficits from birth, is considered one of the most important risk factors for recurrence of seizure. Seizures have also been reported with use of a number of antimicrobial agents, including penicillins, cephalosporins, carbapenems and fluoroquinolones. A review study on antibiotic-induced convulsions suggested that risk factors for antibiotic-induced seizures include renal insufficiency, pre-existing CNS disease (including seizure disorder), cardiopulmonary bypass, sepsis and endocarditis. 3 RMMs: the risk is communicated through the label in SmPC Section 4.4 (Special warnings and precautions for use) CNS = Central nervous system; CT = Computed tomography; RMM = measure; SmPC = Summary of product characteristics. Table 6. Important Potential Risk Drug-Induced Liver Injury DILI is a recognised class effect and it has been observed nonclinical studies; reports indicative of DILI have been received in clinical studies and in the postmarketing setting. History of alcohol use, pre-existing liver disease, concomitant use of other hepatotoxic drugs and infections.
5 Table 6. Important Potential Risk Drug-Induced Liver Injury Routine RMMs: the risk is communicated through the label in SmPC Section 4.8 (Undesirable effects) DILI = Drug induced liver injury; RMM = measure; SmPC = Summary of product characteristics. Table 7. Important Potential Risk Haemolytic Anaemia Haemolytic anaemia is a recognised class effect and it has been observed nonclinical studies; reports indicative of haemolytic anaemia have been received in clinical studies and in the post-marketing setting. Risk factors include autoimmune disease, haematologic neoplasm, immunodeficiency disease, family history of haemolytic disease, and recent viral infections. RMMs: SmPC Section 4.4 (Special warnings and precautions for use) and Section 4.8 (Undesirable effects) RMM = measure; SmPC = Summary of product characteristics. Table 8. Important Potential Risk Renal Impairment (Including Potential Drug Interactions with Nephrotoxic Agents) Renal impairment is a recognised class effect and it has been observed nonclinical studies; reports indicative of renal impairment have been received in clinical studies and in the post-marketing setting. Risk factors include: advanced age, severe life-threatening systemic infections, circulatory, respiratory and renal compromise, trauma, history of diabetes mellitus, hypertension, heart failure, hepatic disease and concomitant nephrotoxic drugs. Clinical use of second- and third-generation cephalosporins has not produced clear evidence of significant nephrotoxicity. Decreases in glomerular filtration rate of about 10 ml/minute were seen after ceftazidime treatment courses ranging from 4-31 days. For many other cephalosporins comparable data are lacking. 4 Drug interactions that may potentially increase the risk of nephrotoxicity cited in the literature mainly relate to the use of older 1st generation cephalosporins (ie, cephaloridine and cefalotin) with either loop diuretics such as furosemide or aminoglycosides. 4 Conflicting data exist concerning the effect of furosemide on the PK of cephalosporins. 5 An increase in aminoglycoside nephrotoxicity has only been documented with cefalotin and cephaloridine. 4 Routine RMMs: the risk is communicated through the label in SmPC Section 4.2 (Posology and method of administration), Section 4.8 (Undesirable effects), and Section 5.2 (Pharmacokinetic properties) PK = Pharmacokinetics; RMM = measure; SmPC = Summary of product characteristics.
6 Table 9. Important Potential Risk Potential for off-label use AMR data was used to identify off-label activities in tigecycline. There is no literature evaluating any off-label use that would be relevant here. Reports indicative of off-label use have been received in the post-marketing setting. Patients with infections who are unresponsive and/or resistant to conventional antibiotic therapy or patients with life-threatening infections where no alternative therapy exists. RMMs: the risk is communicated through the label in SmPC Section 4.1 (Therapeutic indications) and Section 4.2 (Posology and method of administration) AMR = Arlington Medical Resources; PK = Pharmacokinetics; RMM = measure; SmPC = Summary of product characteristics. Table 10. Missing Information - Immunocompromised population Routine RMMs: the risk is communicated through the label in SmPC Section 4.4 (Special warnings and precautions for use) RMM = measure; SmPC = Summary of product characteristics. Table 11. Missing Information - Lactation Routine RMMs: the risk is communicated through the label in SmPC Section 4.6 (Pregnancy and lactation) RMM = measure; SmPC = Summary of product characteristics. Table 12. Missing Information - Paediatric population exposure Additional pharmacovigilance activities Routine RMMs: the risk is communicated through the label in SmPC Section 4.2 (Posology and method of administration) and Section 5.2 (Pharmacokinetic properties) Additional pharmacovigilance activities: Evaluation of the safety data from completed and ongoing PIP studies. See section II.C of this summary for an overview of the post-authorisation development plan. PIP = Paediatric investigation plan; RMM = measure; SmPC = Summary of product characteristics. Table 13. Missing Information - Pre-existing seizure disorder Routine RMMs: the risk is communicated through the label in SmPC Section 4.4 (Special warnings and precautions for use) RMM = measure; SmPC = Summary of product characteristics.
7 Table 14. Missing Information - Pre-existing significant hepatic impairment Routine RMMs: the risk is communicated through the label in SmPC Section 4.2 (Posology and method of administration), Section 4.8 (Undesirable effects), and Section 5.2 (Pharmacokinetic properties) RMM = measure; SmPC = Summary of product characteristics. Table 15. Missing Information - Pregnancy exposure Routine RMMs: the risk is communicated through the label in SmPC Section 4.2 (Posology and method of administration) and Section 5.2 (Pharmacokinetic properties) RMM = measure; SmPC = Summary of product characteristics. Table 16. Missing Information - Efficacy in MRSA CAP Routine RMMs: the risk is communicated through the label in SmPC Section 4.4 (Special warnings and precautions for use) RMM = measure; SmPC = Summary of product characteristics. II.C. Post-Authorisation Development Plan II.C.1. Studies which are Conditions of the Marketing Authorisation There are no studies which are conditions of the marketing authorisation or specific obligation of ZINFORO. II.C.2. Other Studies in Post-Authorisation Development Plan The following category 3 studies are additional pharmacovigilance activities planned or ongoing to address use in paediatric population, (including term and pre-term neonates) and bacterial resistance development. D3720C00009/C /P (PIP) - A multi-centre, open-label study to evaluate the safety, tolerability, PK and efficacy of ceftaroline plus ampicillin plus optional aminoglycoside in term and pre-term neonates with LOS. Purpose of the study: To evaluate the safety, tolerability, PK and efficacy of ceftaroline plus ampicillin plus optional aminoglycoside in term and pre-term neonates with LOS; to evaluate the safety, tolerability, efficacy, and PK of ceftaroline fosamil versus comparator in paediatric subjects with complicated cssti. D3720C00017/C (PIP) - A Phase 4, multi-centre, randomised, observer-blinded study to evaluate the safety, tolerability, efficacy, and PK of ceftaroline fosamil versus comparator in paediatric subjects with cssti.
8 Purpose of the study: To evaluate the safety, tolerability, efficacy, and PK of ceftaroline fosamil versus comparator in paediatric subjects with complicated cssti. Resistance surveillance programme Purpose of the study: To track the longitudinal in-vitro activity of ceftaroline and comparator agents against relevant clinical isolates (those pathogens identified in the SmPC with demonstrated clinical efficacy) in cssti, and LRTI.
9 Risk Management Plan Ceftaroline fosamil References March 2018 REFERENCES Kelkar P, Li J. Cephalosporin allergy. N Engl J Med 2001;345: Stein GE. Antimicrobial resistance in the hospital setting: Impact, trends, and infection control. Pharmacotherapy 2005;25(10 Pt 2):44S- 54S. Wallace KL. Antibiotic-induced convulsions. Crit Care Clin 1997;13(4): Aronson JK. Meyler s side effects of drugs: The international encyclopedia of adverse drug reactions and interactions. 15th ed. Oxford (UK): Elsevier; Cephalosporins. p Furosemide. p Pea F, Furlanut M. Pharmacokinetic aspects of treating infections in the intensive care unit: Focus on drug interactions. Clin Pharmacokinet 2001;40(11):
Summary of risk management plan for Prasugrel Mylan (prasugrel)
EMA/243819/2018 Summary of risk management plan for Prasugrel Mylan (prasugrel) This is a summary of the risk management plan (RMP) for Prasugrel Mylan. The RMP details important risks of prasugrel, how
More informationSummary of risk management plan for Trazimera (trastuzumab)
Summary of risk management plan for Trazimera (trastuzumab) Summary of risk management plan for PF-05280014 (trastuzumab) 1 This is a summary of the RMP for PF-05280014. The RMP details important risks
More informationSummary of risk management plan for Colpermin (peppermint oil)
Part VI: Summary of the risk management plan Summary of risk management plan for Colpermin (peppermint oil) This is a summary of the risk management plan (RMP) for Colpermin. The RMP details important
More informationPART VI: SUMMARY OF THE RISK MANAGEMENT PLAN
PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN Summary of Risk Management Plan for REZOLSTA This is a summary of the risk management plan (RMP) for REZOLSTA. The RMP details important risks of REZOLSTA,
More informationSummary of Activities in the Risk Management Plan (RMP) for DARZALEX (daratumumab)
DARZALEX - Risk Management Plan Summary of Activities in the Risk Management Plan (RMP) for DARZALEX (daratumumab) Document Version: 3.2 Document Date: 14 August 2018 Page 1 / 8 The Risk Management Plan
More informationPART VI: SUMMARY OF THE RISK MANAGEMENT PLAN
PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN Summary of Risk Management Plan for PREZISTA (Darunavir [TMC114]) This is a summary of the risk management plan (RMP) for PREZISTA. The RMP details important
More informationSummary of Risk Management Plan for VOKANAMET (Canagliflozin/Metformin Hydrochloride Fixed Dose Combination)
Summary of Risk Management Plan for VOKANAMET (Canagliflozin/Metformin Hydrochloride Fixed Dose Combination) This is a summary of the risk management plan (RMP) for VOKANAMET. The RMP details important
More informationSummary of the Risk Management Plan
Summary of the Risk Management Plan Summary of Risk Management Plan for Esmya (Ulipristal Acetate) This is a summary of the risk management plan (RMP) for Esmya. The RMP details important risks of Esmya,
More informationPART VI Summary of the RMP
PART VI Summary of the RMP Summary of Risk Management Plan for ORKAMBI This is a summary of the risk management plan (RMP) for ORKAMBI. The RMP details important risks of ORKAMBI, how these risks can be
More informationSummary of risk management plan for Dzuveo (Sufentanil (as citrate))
Part VI: Summary of the risk management plan Summary of risk management plan for Dzuveo (Sufentanil (as citrate)) This is a summary of the risk management plan (RMP) for Dzuveo. The RMP details important
More informationPART VI: SUMMARY OF THE RISK MANAGEMENT PLAN
PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN VI.1 Summary of risk management plan for RELVAR ELLIPTA (fluticasone furoate/vilanterol) This is a summary of the risk management plan (RMP) for RELVAR ELLIPTA.
More informationSwiss Summary of the Risk Management Plan (RMP) for Parsabiv (Etelcalcetide)
Swiss Summary of the Risk Management Plan (RMP) for Parsabiv (Etelcalcetide) RMP Summary: Version 2, November 2018 Page 1 of 9 EU RMP: Version 2.0, August 2018 The Risk Management Plan (RMP) is a comprehensive
More informationSummary of risk management plan for Nerlynx
Summary of risk management plan for Nerlynx This is a summary of the risk management plan (RMP) for Nerlynx. The RMP details important risks of Nerlyx, how these risks can be minimised, and how more information
More informationZinplava Swiss Risk Management Plan Summary V1.5. Swiss Summary of the Risk Management Plan (RMP) for. Zinplava. (Bezlotoxumab 1000mg)
Swiss Summary of the Risk Management Plan (RMP) for (Bezlotoxumab 1000mg) Concentrate for solution for infusion Version 1.5 (November 2016) The Risk Management Plan (RMP) is a comprehensive document submitted
More informationSummary of the risk management plan (RMP) for Zerbaxa (ceftolozane / tazobactam)
EMA/513109/2015 Summary of the risk management plan (RMP) for Zerbaxa (ceftolozane / tazobactam) This is a summary of the risk management plan (RMP) for Zerbaxa, which details the measures to be taken
More informationCHMP List of questions
28 June 2018 EMA/CHMP/346196/2018 To be addressed by the marketing authorisation holders for bacterial lysatescontaining medicinal products for respiratory conditions Referral under Article 31 of Directive
More informationSummary of risk management plan for Ulunar Breezhaler (Indacaterol/glycopyrronium)
Part VI: Summary of the risk management plan Summary of risk management plan for Ulunar Breezhaler (Indacaterol/glycopyrronium) This is a summary of the RMP for Ulunar Breezhaler. The RMP details important
More informationImportant new concerns or changes to the current ones will be included in updates of YESCARTA s RMP.
PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN Summary of risk management plan for YESCARTA (axicabtagene ciloleucel) This is a summary of the risk management plan (RMP) for YESCARTA. The RMP details important
More informationImportant new concerns or changes to the current ones will be included in updates of Symtuza's RMP.
Summary of Risk Management Plan for Symtuza (D/C/F/TAF) This is a summary of the risk management plan (RMP) for Symtuza. The RMP details important risks of Symtuza, how these risks can be minimised, and
More informationSummary of product characteristics (SmPC)
Summary of product characteristics (SmPC) What is it and what does it contain? An agency of the European Union Table of contents 1.What is the summary of product characteristics (SmPC)? 2.Where SmPC information
More informationSummary of risk management plan for OPDIVO (nivolumab)
Summary of risk management plan for OPDIVO (nivolumab) This is a summary of the risk management plan (RMP) for OPDIVO. The RMP details important risks of OPDIVO, how these risks can be minimized, and how
More informationPART VI: SUMMARY OF THE RISK MANAGEMENT PLAN 2 RISKS ASSOCIATED WITH THE MEDICINE AND ACTIVITIES TO MINIMIZE OR FURTHER CHARACTERISE THE RISKS
PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN Summary of risk management plan for Briviact This is a summary of the risk management plan (RMP) for Briviact. The RMP details important risks of Briviact,
More informationSummary of risk management plan for Methylphenidate modifiedrelease hard capsules (methylphenidate)
Part VI: Summary of the risk management plan Summary of risk management plan for Methylphenidate modifiedrelease hard capsules (methylphenidate) This is a summary of the risk management plan (RMP) for
More informationSummary of risk management plan for OPDIVO (nivolumab)
Summary of risk management plan for OPDIVO (nivolumab) This is a summary of the risk management plan (RMP) for OPDIVO. The RMP details important risks of OPDIVO, how these risks can be minimized, and how
More informationSummary of the risk management plan (RMP) for Elocta (efmoroctocog alfa)
EMA/707623/2015 Summary of the risk management plan (RMP) for Elocta (efmoroctocog alfa) This is a summary of the risk management plan (RMP) for Elocta, which details the measures to be taken in order
More informationPart VI: Summary of the risk management plan by product
Version 1.3, 28-Dec-2015 Risk Management Plan of a fixed combination of Dexketoprofen trometamol and Tramadol hydrochloride (oral formulation) Part VI: Summary of the risk management plan by product VI.1
More informationSummary of the risk management plan (RMP) for Vizamyl (flutemetamol 18 F)
EMA/404996/2014 Summary of the risk management plan (RMP) for Vizamyl (flutemetamol 18 F) This is a summary of the risk management plan (RMP) for Vizamyl, which details the measures to be taken in order
More informationVI.2 ELEMENTS FOR A PUBLIC SUMMARY (VOLUVEN 10%)
VI.2 ELEMENTS FOR A PUBLIC SUMMARY (VOLUVEN 10%) VI.2.1 OVERVIEW OF DISEASE EPIDEMIOLOGY Hypovolaemia is a state of decreased or reduced circulating blood volume which can be caused by a number of medical
More informationThe safety concerns defined with the reference product apply to Buprenorphine-Naloxone 2/0.5 mg, 8/2 mg, sublingual tablets.
These products are indicated in the substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter
More informationPackage leaflet: Information for the user Zinforo 600 mg powder for concentrate for solution for infusion Ceftaroline fosamil
Package leaflet: Information for the user Zinforo 600 mg powder for concentrate for solution for infusion Ceftaroline fosamil Read all of this leaflet carefully before you start using this medicine because
More informationElements for a Public Summary
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Rapenin (phenoxymethylpenicillin potassium) is indicated for the treatment of infections caused by penicillin-sensitive bacteria.
More informationPart VI: Summary of the risk management plan by product
Part VI: Summary of the risk management plan by product VI.1 Elements for summary tables in the EPAR VI.1.1 Summary table of Safety concerns Summary of safety concerns Important identified risks Hepatotoxic
More informationElements for a Public Summary. Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Pneumococcal infection is a major cause of morbidity mortality worldwide. In 2005, WHO estimated that 1.6 million deaths were
More informationSummary of the risk management plan (RMP) for Scenesse (afamelanotide)
EMA/692496/2014 Summary of the risk management plan (RMP) for Scenesse (afamelanotide) This is a summary of the risk management plan (RMP) for Scenesse, which details the measures to be taken in order
More informationSWISS SUMMARY OF THE RISK MANAGEMENT PLAN (RMP) FOR ZERBAXA. (Ceftolozane/Tazobactam)
PAGE 1 SWISS SUMMARY OF THE RISK MANAGEMENT PLAN (RMP) FOR ZERBAXA (Ceftolozane/Tazobactam) Active substance(s): Ceftolozane/Tazobactam Product(s) concerned: ZERBAXA Market Authorisation Holder: MSD Merck
More informationVPRIV EU-RMP Version 9.2. Elements for a Public Summary. Overview of Disease Epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of Disease Epidemiology Gaucher disease is a rare genetic illness due to the absence of a specific enzyme in the body. About 30,000 persons worldwide
More informationMesporin TM. Ceftriaxone sodium. Rapid onset, sustained action, for a broad spectrum of infections
Ceftriaxone sodium Rapid onset, sustained action, for a broad spectrum of infections 1, 2, 3 Antibiotic with a broad spectrum of activity Broad spectrum of activity against gram-positive* and gram-negative
More informationEnpr-EMA PAEDIATRIC ANTIBIOTIC WORKING GROUP
Enpr-EMA PAEDIATRIC ANTIBIOTIC WORKING GROUP Rationale and outlook Laura Folgori Clinical Research Fellow Paediatric Infectious Diseases Research Group St George s University of London RATIONALE The work
More informationSummary of the risk management plan (RMP) for Nucala (mepolizumab)
EMA/671186/2015 Summary of the risk management plan (RMP) for Nucala (mepolizumab) This is a summary of the risk management plan (RMP) for Nucala, which details the measures to be taken in order to ensure
More informationPART VI: SUMMARY OF THE RISK MANAGEMENT PLAN BY PRODUCT
PAGE 175 PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN BY PRODUCT Summary of risk management plan for pembrolizumab This is a summary of the risk management plan (RMP) for pembrolizumab. The RMP details
More informationAnnex I: Proposed Core Safety Profile (CSP) 4.3 Contraindications
Annex I: Proposed Core Safety Profile (CSP) 4.3 Contraindications Hypersensitivity to cefuroxime or to any of the excipients listed in section 6.1. Patients with known hypersensitivity to cephalosporin
More informationSUMMARY OF THE RISK MANAGEMENT PLAN FOR. BESPONSA 1mg (INOTUZUMAB OZOGAMICIN) Powder for concentrate for solution for infusion.
SUMMARY OF THE RISK MANAGEMENT PLAN FOR BESPONSA 1mg (INOTUZUMAB OZOGAMICIN) Powder for concentrate for solution for infusion. This RMP Summary is based on Part VI of the EU RMP for BESPONSA (Inotuzumab
More informationVancomycin Orion , Version 2 Public Summary of the Risk Management Plan
Vancomycin Orion 18.1.2016, Version 2 Public Summary of the Risk Management Plan VI.2 Elements for a Public Summary Vancomycin Orion is intravenously administered glycopeptide antibiotic. It is indicated
More informationElements for a Public Summary Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Acute pain usually responds to medication and should settle in less than three months. Inadequate pain relief may lead to other
More informationSummary of the risk management plan (RMP) for Vimizim (elosulfase alfa)
EMA/127543/2014 Summary of the risk management plan (RMP) for Vimizim (elosulfase alfa) This is a summary of the risk management plan (RMP) for Vimizim, which details the measures to be taken in order
More informationSummary of the risk management plan (RMP) for Ebymect (dapagliflozin / metformin)
EMA/672415/2015 Summary of the risk management plan (RMP) for Ebymect (dapagliflozin / metformin) This is a summary of the risk management plan (RMP) for Ebymect, which details the measures to be taken
More informationVANLID Capsules (Vancomycin hydrochloride)
Published on: 22 Sep 2014 VANLID Capsules (Vancomycin hydrochloride) Composition VANLID Capsules Each capsule contains: Vancomycin Hydrochloride IP equivalent to Vancomycin.. 250 mg Approved colours used
More informationRisk What is known Preventability Known hypersensitivity to macrolide antibiotic drugs or to any of its excipients.
VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology Clarithromycin 500 mg, powder for solution for infusion is indicated when parenteral therapy is required for treatment of severe
More informationElements for a Public Summary
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Alzheimer's disease is the most common form of dementia, a general term for memory loss and other intellectual abilities serious
More informationSummary of risk management plan for Rizmoic (naldemedine)
Summary of risk management plan for Rizmoic (naldemedine) This is a summary of the risk management plan (RMP) for Rizmoic. The RMP details important risks of Rizmoic, how these risks can be minimised,
More informationSummary of the risk management plan (RMP) for Pregabalin Pfizer (pregabalin)
EMA/247834/2014 Summary of the risk management plan (RMP) for Pregabalin Pfizer (pregabalin) Overview of disease epidemiology Epilepsy Epilepsy is a long-term condition affecting the brain and is characterised
More informationVANCOMYCIN ALTIEX. 500 mg & 1000 mg pulver til koncentrat til infusionsvæske, opløsning
VANCOMYCIN ALTIEX 500 mg & 1000 mg pulver til koncentrat til infusionsvæske, opløsning VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Vancomycin is an antibiotic that is used
More informationSummary of the risk management plan (RMP) for Zykadia (ceritinib)
EMA/154751/2015 Summary of the risk management plan (RMP) for Zykadia (ceritinib) This is a summary of the risk management plan (RMP) for Zykadia, which details the measures to be taken in order to ensure
More informationAnnex III. Amendments to relevant sections of the product information
Annex III Amendments to relevant sections of the product information Note: These amendments to the relevant sections of the Summary of Product Characteristics and Package Leaflet are the outcome of the
More informationSummary of the risk management plan (RMP) for Izba (travoprost)
EMA/14138/2014 Summary of the risk management plan (RMP) for Izba (travoprost) This is a summary of the risk management plan (RMP) for Izba, which details the measures to be taken in order to ensure that
More informationHealth Products Regulatory Authority IPAR. Public Assessment Report. Scientific discussion
IPAR Public Assessment Report Scientific discussion Magnaspartate 243mg Powder for Oral Solution MAGNESIUM ASPARTATE DIHYDRATE IE/H/436/001/DC Date: 3 rd November 2014 This module reflects the scientific
More informationSummary of the risk management plan (RMP) for Spectrila (asparaginase)
EMA/829066/2015 Summary of the risk management plan (RMP) for Spectrila (asparaginase) This is a summary of the risk management plan (RMP) for Spectrila, which details the measures to be taken in order
More informationSummary of the risk management plan (RMP) for Nivolumab BMS (nivolumab)
EMA/359171/2015 Summary of the risk management plan (RMP) for Nivolumab BMS (nivolumab) This is a summary of the risk management plan (RMP) for Nivolumab BMS, which details the measures to be taken in
More informationRisk Management Plan Summary
Risk Management Plan Summary TREMFYA (guselkumab) 100 mg/ml pre-filled syringe Document Version: 1.0 (11.07.2018) Based on EU RMP version 1.2 Marketing authorization holder: Janssen-Cilag AG, Gubelstr.
More informationElements for a public summary
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Nevirapine is used for antiretroviral combination therapy of Human Immunodeficiency Virus (HIV) infection. Human immunodeficiency
More informationPHARMACOVIGILANCE GLOSSARY
PHARMACOVIGILANCE GLOSSARY Section 1 Section 2 Section 3 Section 4 Definitions of terminology used for side effects Definitions of drug safety terms Definitions of risk terminology Definitions of general
More informationEU Risk Management Plan PUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) EpiPen 0.3 mg / EpiPen Jr mg DATE: , VERSION 4.
PUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) DATE: 23.11.2016, VERSION 4.0 VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology The incidence of anaphylaxis is 4 50 per 100,000 persons/year
More informationSummary Public Assessment Report. non-generics. Folic acid Colonis Folic acid MT/H/0203/001/DC
CMDh/233/2011 June 2014 Summary Public Assessment Report non-generics Folic acid Colonis Folic acid MT/H/0203/001/DC Date: 18 th November, 2016 Summary PAR non-generics 1/4 Summary Public Assessment Report
More informationBRISTOL-MYERS SQUIBB RESEARCH & DEVELOPMENT SWISS SUMMARY OF THE RISK MANAGEMENT PLAN FOR NIVOLUMAB (NIVOLUMAB IS THE ACTIVE SUBSTANCE IN OPDIVO )
BRISTOL-MYERS SQUIBB RESEARCH & DEVELOPMENT SWISS SUMMARY OF THE RISK MANAGEMENT PLAN FOR NIVOLUMAB (NIVOLUMAB IS THE ACTIVE SUBSTANCE IN OPDIVO ) Version Number: 7 Document Date: 13-Dec-2018 Bristol-Myers
More informationPLENADREN EU-RMP VERSION 3.2. Elements for a Public Summary. Overview of Disease Epidemiology
PLENADREN EU-RMP VERSION 3.2 VI.2 VI.2.1 Elements for a Public Summary Overview of Disease Epidemiology PLENADREN contains hydrocortisone and is used to treat adrenal insufficiency (AI) in adults. AI occurs
More informationScientific conclusions
Annex II Scientific conclusions and grounds for amendment of the summary of product characteristics, labelling and package leaflet presented by the European Medicines Agency 24 Scientific conclusions Overall
More informationSummary of the risk management plan (RMP) for Rixubis (nonacog gamma)
EMA/677082/2014 Summary of the risk management plan (RMP) for Rixubis (nonacog gamma) This is a summary of the risk management plan (RMP) for Rixubis, which details the measures to be taken in order to
More informationSummary of the risk management plan (RMP) for Oncaspar (pegaspargase)
EMA/829065/2015 Summary of the risk management plan (RMP) for Oncaspar (pegaspargase) This is a summary of the risk management plan (RMP) for Oncaspar, which details the measures to be taken in order to
More informationPUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) CANDESARTAN/HYDROCHLOROTHIAZIDE ORION 8 MG/12.5 MG, 16 MG/12.5 MG, 32 MG/12.5 MG, 32 MG/25 MG ORION
PUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) CANDESARTAN/HYDROCHLOROTHIAZIDE ORION 8 MG/12.5 MG, 16 MG/12.5 MG, 32 MG/12.5 MG, 32 MG/25 MG ORION CORPORATION DATE: 17-04-2015, VERSION 2 VI.2 Elements for
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Zinforo 600 mg powder for concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains
More informationVI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology VI.2.2 Summary of treatment benefits
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Human immunodeficiency virus (HIV) is a virus that attacks your body s natural defense system and causes acquired immunodeficiency
More informationSummary of the risk management plan (RMP) for Rezolsta (darunavir / cobicistat)
EMA/608280/2014 Summary of the risk management plan (RMP) for Rezolsta (darunavir / cobicistat) This is a summary of the risk management plan (RMP) for Rezolsta, which details the measures to be taken
More informationEuropean Medicines Agency decision
EMA/202840/2012 European Medicines Agency decision P/0072/2012 of 24 April 2012 on the acceptance of a modification of an agreed paediatric investigation plan for ceftaroline fosamil (EMEA-000769-PIP01-09-M02)
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET 1. PRODUCT NAME Zinforo 600 mg powder for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains ceftaroline fosamil acetic acid solvate monohydrate equivalent
More informationElements for a public summary. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Nosocomial pneumonia (NP): NP (hospital acquired pneumonia) is most common in elderly patients; however, patients of any age may
More informationVancomycin Orion , Version 1.0. Public Summary of the Risk Management Plan
Vancomycin Orion 18.6.2015, Version 1.0 Public Summary of the Risk Management Plan VI.2 Elements for a Public Summary Vancomycin Orion is intravenously administered glycopeptide antibiotic. It is indicated
More informationAnnex II. Scientific conclusions and grounds for variation to the terms of the marketing authorisations
Annex II Scientific conclusions and grounds for variation to the terms of the marketing authorisations 12 Scientific conclusions and grounds for variation to the terms of the marketing authorisations The
More informationRasburicase 1.5 mg/ml powder and solvent for concentrate for solution for infusion. FASTURTEC
For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory This package insert is continually updated. Please read carefully before using a new pack. Rasburicase 1.5 mg/ml powder
More informationSummary of the risk management plan (RMP) for Opdivo (nivolumab)
EMA/285771/2015 Summary of the risk management plan (RMP) for Opdivo (nivolumab) This is a summary of the risk management plan (RMP) for Opdivo, which details the measures to be taken in order to ensure
More informationFIS 2013, Birmingham
Fidaxomicin: CDDFT Case Studies Dr Deepa Nayar County Durham and Darlington Foundation Trust FIS 2013, Birmingham This meeting has been initiated and funded by Astellas Pharma Ltd. County Durham and Darlington
More informationProduct. Commission. Summary Notification 1. Information issued on. Decision. Issued 2 / affected 3 amended on
Procedural steps taken and scientific information after the authorisation Changes made after 1 January 2005 For procedures finalised before 1 January 2001, please refer to Procedural steps taken until
More informationSummary of the risk management plan (RMP) for Hemangiol (propranolol)
EMA/122592/2014 Summary of the risk management plan (RMP) for Hemangiol (propranolol) This is a summary of the risk management plan (RMP) for Hemangiol, which details the measures to be taken in order
More informationRisk Management Plan
Management Plan Active substance: VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Hypertension is generally defined as blood pressure higher than 140/90 mmhg. Hypertension may
More informationFasturtec 1.5 mg/ml powder and solvent for concentrate for solution for infusion.
1. NAME OF THE MEDICINAL PRODUCT Fasturtec 1.5 mg/ml powder and solvent for concentrate for solution for infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION After reconstitution, 1 ml of Fasturtec concentrate
More informationInfections Amenable to OPAT. (Nabin Shrestha + Ajay Mathur)
3 Infections Amenable to OPAT (Nabin Shrestha + Ajay Mathur) Decisions regarding outpatient treatment of infections vary with the institution, the prescribing physician, the individual patient s condition
More informationExtrapolation in antibacterial agents
Extrapolation in antibacterial agents Irja Lutsar University of Tartu, Estonia Maria Fernandez Cortizo- Medicines Agency, Spain EMA meeting, 30.09.2015 Glossary PIP: Paediatric Investigation Plan AHOM:
More informationPUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) CIPROFLOXACIN ORION 750 MG FILM-COATED TABLETS ORION OYJ DATE: , VERSION 1.
PUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) CIPROFLOXACIN ORION 250 MG FILM-COATED TABLETS CIPROFLOXACIN ORION 500 MG FILM-COATED TABLETS CIPROFLOXACIN ORION 750 MG FILM-COATED TABLETS ORION OYJ DATE:
More informationWARNING: TENDON EFFECTS and EXACERBATION OF MYASTHENIA GRAVIS
DECLESAU (dergrafloxacin) tablets, for oral use DECLESAU (dergrafloxacin) injection, solution for intravenous use WARNING: TENDON EFFECTS and EXACERBATION OF MYASTHENIA GRAVIS Fluoroquinolones, including
More informationPregabalin Aristo Version: RMP-Pregabalin0
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Epilepsy Epilepsy is a long-term condition affecting the brain and is characterised by recurring seizures (or fits). It is one
More informationAnnex I. Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)
Annex I Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s) 1 Scientific conclusions Taking into account the PRAC Assessment Report on the PSUR(s) for captopril
More informationSummary of the risk management plan (RMP) for Aripiprazole Mylan Pharma (aripiprazole)
EMA/370707/2016 Summary of the risk management plan (RMP) for Aripiprazole Mylan Pharma (aripiprazole) This is a summary of the risk management plan (RMP) for Aripiprazole Mylan Pharma, which details the
More informationAnnex I. Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)
Annex I Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s) Scientific conclusions Taking into account the PRAC Assessment Report on the PSUR(s) for domperidone,
More informationAnnex IV Scientific conclusions
Annex IV Scientific conclusions 56 Scientific conclusions On 7 June 2017, the European Commission (EC) was informed of a fatal case of fulminant liver failure in a patient treated with daclizumab in an
More informationSummary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT Fucidin 20mg/g Cream Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each gram of cream contains 20mg fusidic acid. Excipients with known effect:
More informationCHMP extension of indication variation assessment report
23 April 2015 EMA/CHMP/245949/2015 adopted Committee for Medicinal Products for Human Use (CHMP) Invented name: Tygacil International non-proprietary name: TIGECYCLINE Procedure No. EMEA/H/C/000644/II/0092
More informationZerlinda (MRP DK/H/2265/001)
Zerlinda (MRP DK/H/2265/001) VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Prevention of bone complications, e.g. fractures, in adult patients with bone metastases (spread
More information